MARKET

IGC

IGC

IGC Pharma Inc
AMEX
0.3027
+0.0026
+0.87%
After Hours: 0.3083 +0.0056 +1.85% 19:57 12/08 EST
OPEN
0.3130
PREV CLOSE
0.3000
HIGH
0.3130
LOW
0.3000
VOLUME
80.05K
TURNOVER
0
52 WEEK HIGH
0.4858
52 WEEK LOW
0.2666
MARKET CAP
19.29M
P/E (TTM)
-1.4948
1D
5D
1M
3M
1Y
5Y
'Republican Representative David Joyce To Introduce Cannabis Legalization Bill' - Forbes
Benzinga · 2d ago
IGC Pharma Announces Collaboration With Los Andes University's Center For Research And Training In Artificial Intelligence To Integrate AI Into Clinical Trials
Benzinga · 2d ago
Weekly Report: what happened at IGC last week (1127-1201)?
Weekly Report · 4d ago
'German Lawmakers Reach Agreement On Revised Marijuana Legalization Bill, With Final Vote Expected Next Week' -Marijuana Moment Report
Benzinga · 11/27 15:59
Weekly Report: what happened at IGC last week (1120-1124)?
Weekly Report · 11/27 10:18
AI And THC: IGC Pharma Teams Up With Colombian University For Alzheimer's Treatment Research
Igc pharma has entered into a master cooperation agreement with the university of los andes to integrate ai into drug development and clinical trials. Igc pharma's leading drug, igc-ad1, is in phase 2 trials for treating agitation related to alzheimer's disease symptoms.
Benzinga · 11/22 04:16
Weekly Report: what happened at IGC last week (1113-1117)?
Weekly Report · 11/20 10:16
India Globalization Capital GAAP EPS of -$0.05, revenue of $0.29M
India globalization capital reports q2 gaap eps of -$0.05, revenue of $0.29m (+45.0% y/y). The company's revenue was up 45% from the same period last year. Igc is a subsidiary of india globalization pharma, inc.
Seeking Alpha · 11/13 19:35
More
About IGC
IGC Pharma, Inc. is a clinical-stage pharmaceutical company. It develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome, and chronic pain. Its segments include Life Sciences and Infrastructure. It has two investigational drug assets targeting Alzheimer’s disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (THC) based formulation that is in a 146-person phase II clinical trial for agitation in dementia due to Alzheimer’s. TGR-63, a non-cannabinoid molecule, is an enzyme inhibitor shown in pre-clinical trials to reduce neurotoxicity in Alzheimer’s cell lines. It also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.

Webull offers IGC Pharma Inc stock information, including AMEX: IGC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IGC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IGC stock methods without spending real money on the virtual paper trading platform.